Eight Roads-backed PlasmaGen Biosciences raises Rs 150 crore at Rs 1,500 crore valuation

Share via:



PlasmaGen Biosciences has raised Rs 150 crore led by ViNS Bioproducts, with participation from high-net-worth individuals (HNIs), family offices, pharma entrepreneurs, and existing investors. The Bengaluru-based startup that’s backed by Eight Road Ventures secured the funding at a valuation of over Rs 1,500 crore.

The lead investor, ViNS, a 28-year old pharma company, develops and manufactures antivenom for snake and scorpion bites, antitoxins for tetanus, diphtheria, gangrene, and anti-rabies serums.

Founded in 2010, PlasmaGen develops and…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Popular

More Like this

Eight Roads-backed PlasmaGen Biosciences raises Rs 150 crore at Rs 1,500 crore valuation



PlasmaGen Biosciences has raised Rs 150 crore led by ViNS Bioproducts, with participation from high-net-worth individuals (HNIs), family offices, pharma entrepreneurs, and existing investors. The Bengaluru-based startup that’s backed by Eight Road Ventures secured the funding at a valuation of over Rs 1,500 crore.

The lead investor, ViNS, a 28-year old pharma company, develops and manufactures antivenom for snake and scorpion bites, antitoxins for tetanus, diphtheria, gangrene, and anti-rabies serums.

Founded in 2010, PlasmaGen develops and…



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

More like this

9to5Mac Overtime 054: How’s it better than AltaVista?

Jeff is the head of video content production...

Python: What’s Coming in 2026

If 2025 was “the year of type checking...

Did you receive a mail to reset Instagram password?...

After several Instagram users last week reported receiving...

Popular

iptv iptv iptv